Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on September 8, 2014, covering events occurring on September 4, 2014. The filing details the results of the company's 2014 Annual Meeting of Stockholders and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and voting results rather than financial performance.
Material Changes and Corporate Actions
- Board Appointment: William H. Nelson was elected to the Board of Directors and appointed to the Audit, Compensation, and Nominations and Corporate Governance Committees, serving as Chair of the latter.
- Compensation: Mr. Nelson was granted 6,623 restricted stock units (RSUs) vesting quarterly over one year, plus eligibility for standard cash compensation for non-employee directors.
- Share Authorization: Stockholders approved an amendment to decrease authorized common shares from 395,000,000 to 90,000,000.
Annual Meeting Voting Results
The following proposals were voted on at the Annual Meeting held on September 4, 2014:
| Proposal | For | Against | Abstain | Result |
|---|---|---|---|---|
| Election of 5 Directors (including W.H. Nelson) | Varied (5.3M - 5.5M) | N/A | N/A | Approved |
| Ratify Auditor (KMJ Corbin and Company, LLP) | 5,513,990 | 0 | 19,228 | Approved |
| Decrease Authorized Shares | 5,520,218 | 5,829 | 7,171 | Approved |
Outlook and Risks
The filing does not contain management commentary on future financial guidance, specific risks, or contingencies. The primary focus is the successful ratification of the auditor and the reduction of authorized share capital.
Investor Verification Checklist
- Verify the identity of the registrant as Imprimis Pharmaceuticals, Inc., noting the discrepancy with the "Harrow, Inc." label in the request metadata.
- Confirm the impact of the authorized share reduction (from 395M to 90M) on future capital raising capabilities.
- Review the 2014 Definitive Proxy Statement for details on the standard cash compensation program for non-employee directors.
- Check subsequent filings for the vesting schedule and financial impact of the 6,623 RSUs granted to William H. Nelson.